3P Biopharmaceuticals is a Contract Development and Manufacturing Organization (CDMO) based in Europe specialized in the development and GMP manufacture of biopharmaceutical products for clinical and commercial supply.
Quality, flexibility and attention to detail form the cornerstones of 3P’s operation ensuring that the customer’s project is delivered on time and to budget.
3P has extensive experience with different mammalian (e.g. CHO, BHK-21, HEK293, Hybridomas) and microbial (e.g. E. coli, S. cerevisiae, H. polymorpha, P. pastoris) expression systems to produce New Biologic Entities (NBEs) like fusion proteins, vaccines and monoclonal antibodies as well as biosimilar products.
With a state-of-the-art facility based in Spain that is regulated and authorised by the European Medicines Agency (EMA) for clinical and commercial production of biologics up to BSL-2, the facility is also inspected and approved by the US FDA for manufacture of products destined for the US market.
3P continues to drive its business forward and has entered a significant growth phase with expansion of its capabilities in terms of operational scale and headcount to serve an ever-growing global customer base.